Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 2, 2005, Pages 726-733

  Gaudreault, Jacques ^a   Fei, David ^a   Rusit, Jeriza ^a   Suboc, Pamela ^a   Shiu, Vanessa ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RANIBIZUMAB; TRASTUZUMAB; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; MONKEY; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG EVALUATION, PRECLINICAL; FEMALE; HALF-LIFE; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS; MACACA FASCICULARIS; MALE; RECOMBINANT FUSION PROTEINS; RETINA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 13944266313     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-0601     Document Type: Article

References (37)

1. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988;32.375-413.
2. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol. 1980;24:335-610.
3. D'Amico DJ. Diseases of the retina. N Engl J Med. 1994;331:95-106.
4. Tolentino MJ, Miller JW, Gragoudas ES, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1990;114:964-970.
5. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37: 1929-1934.
6. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
7. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
8. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
9. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
10. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol. 1994;112:1476-1482.
11. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 1995;72: 638-645.
12. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001;114: 853-865.
13. Kim I, Ryan AM, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci. 1999;40:2115-2121.
14. Gerhardinger C, Brown LF, Roy S, et al. Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy. Am J Pathol. 1998;152:1453-1462.
15. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med. 1995;1:182-193.
16. Shima DT, Gougos A, Miller JW, et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci. 1996;37:1334-1340.
17. Stump DC, Mann KG. Mechanisms of thrombus formation and lysis. Ann Emerg Med. 1988;17:1138-1147.
18. Gaudreault J, Webb W, Van Hoy M, et al. Pharmacokinetics and retinal distribution of AMD rhufab V2 after intravitreal administration in rabbits. AAPS Pharm Sci. 1999;(suppl 1):3207.
19. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27: 536-544.
20. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25.
21. Maurice DM, Mishima S. Ocular pharmacokinetics. In: Scare M, ed. Pharmacology of the Eye. Berlin: Springer-Verlag; 1984:19-116.
22. Gupta SK, Velpandian T, Dhingra N, Jaiswal J. Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. J Ocul Pharmacol Ther. 2000;16:511-518.
23. Pearson PA, Hainsworth DP, Ashton P. Clearance and distribution of ciprofloxacin after intravitreal injection. Retina. 1993;13:326-330.
24. Maurice D. Protein dynamics in the eye studies with labeled proteins. Am J Ophthalmol. 1959;47:361-367.
25. Mordenti J, Thomsen K, Licko V, et al. Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol Sci. 1999;52:101-106.
26. Maurice DM. Injection of drugs into the vitreous body. In: Leopold I, Burns R, ed. Symposium on Ocular Therapy. New York: John Wiley & Sons; 1976:59-72.
27. Leeds JM, Henry SP, Bistner S, et al. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys. Drug Metab Dispos. 1998;26:670-675.
28. Brizzi MF, Formato L, Bonamini R. The molecular mechanisms of angiogenesis: a new approach to cardiovascular diseases. Ital Heart J. 2001;2:81-92.
29. Croll SD, Wiegand SJ. Vascular growth factors in cerebral ischemia. Mol Neurobiol. 2001;23:121-135.
30. Miraliakbari R, Francalancia NA, Lust RM, et al. Differences in myocardial and peripheral VEGF and KDR levels after acute ischemia. Ann Thorac Surg. 2000;69:1750-1753.
31. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81:154-162.
32. Yoshida A, Yoshida S, Ishibashi T, Inomata H. Intraocular neovascularization. Histol Histopathol. 1999;14:1287-1294.
33. Lutty GA, McLeod DS, Merges C, Diggs A, Plouet J. Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol. 1996;114:971-977.
34. Adamis AP, Shima DT, Yeo KT, et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun. 1993;193:631-638.
35. Nomura M, Yamagishi S, Harada S, et al. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem. 1995;270:28316-28324.
36. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113:1538-1544.
37. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293: 865-881.